Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Medication: Clinical trial

Journal articles and book chapters

11-06-2018 | Nephropathy | Article

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): A randomized, placebo-controlled, phase 2 trial

de Zeeuw D et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30289-4

11-03-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

10-21-2018 | Sitagliptin | Article

A randomized clinical trial to evaluate the single‐dose pharmacokinetics, pharmacodynamics and safety of sitagliptin in pediatric patients with type 2 diabetes

Fraser IP et al. Pediatr Diabetes 2018. doi: 10.1111/pedi.12790

08-29-2018 | Hypoglycemia | Article

A post hoc pooled analysis to evaluate hypoglycemia risk with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in people with type 2 diabetes on a basal‐only insulin regimen

Bolli GB et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13515

08-21-2018 | Dulaglutide | Article

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulfonylurea: A 52‐week open‐label, randomized phase 3 trial

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

08-15-2018 | Insulin glargine | Article

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase 3 INSTRIDE 2 study

Blevins TC et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13495

08-13-2018 | Insulin glargine | Article

More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: The randomized head-to-head BRIGHT trial

Rosenstock J et al. Diabetes Care 2018: dc180559. doi: 10.2337/dc18-0559

08-05-2018 | Exenatide | Article

Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial

Jabbour SA et al. Diabetes Care 2018: dc180680. doi: 10.2337/dc18-0680

08-02-2018 | Diabetic foot | Article

The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial

Dhatariya K et al. Diabetes Care 2018: dc181094. doi: 10.2337/dc18-1094

07-19-2018 | Dapagliflozin | Article

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial

Methieu C et al. Diabetes Care 2018: dc180623. doi: 10.2337/dc18-0623

07-19-2018 | Semaglutide | Article

A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin

Lingvay I et al. Diabetes Care 2018: dc172381. doi: 10.2337/dc17-2381

07-16-2018 | Ipragliflozin | Article

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

Ishihara H et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0359-x

06-30-2018 | Insulin NPH | Article

Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine Hagedorn insulin protocol: A randomized clinical trial

Khowaja A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0468-3

06-27-2018 | Metformin | Article

Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan

Matsuura N et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0361-3

06-27-2018 | Hyperglycemia | Article

Contribution of BHG and PPHG to overall hyperglycemia in T2DM patients treated with LM25 and LM50: Post hoc analysis of a randomized crossover trial

Li W et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0462-9

06-25-2018 | Type 2 diabetes | Article

Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test

The RISE Consortium. Diabetes Care 2018. doi: 10.2337/dc18-0243

06-25-2018 | Type 2 diabetes | Article

Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp

The RISE Consortium. Diabetes Care 2018. doi: 10.2337/dc18-0244

06-25-2018 | Type 2 diabetes | Article

Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes

The RISE Consortium. Diabetes Care 2018. doi: 10.2337/dc18-0787

06-24-2018 | Sotagliflozin | Article

Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The North American inTandem1 study

Buse JB et al. Diabetes Care 2018. doi: 10.2337/dc18-0343

06-23-2018 | Sitagliptin | Article

Efficacy and safety of sitagliptin in Hispanic/Latino patients with type 2 diabetes: A pooled analysis from ten randomized, placebo-controlled phase 3 clinical trials

Raji A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0461-x

Next
Image Credits